
Sign up to save your podcasts
Or


In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
By American College of Cardiology3.8
5858 ratings
In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

518 Listeners

321 Listeners

504 Listeners

167 Listeners

906 Listeners

21 Listeners

31 Listeners

298 Listeners

3,374 Listeners

138 Listeners

1,150 Listeners

39 Listeners

367 Listeners

437 Listeners

32 Listeners